Early Access — free while we kick the tires
EdgarHawk

Moat Ross

CHIEF COMMERCIAL OFFICER

Officer
2 filings analyzed · 1 company · Latest 2025-05-01

Companies

Company Buys Sells Direction
Kiniksa Pharmaceuticals International, plc KNSA 0 20 Net selling

Activity

May 2025
Sell
87,269 shares
$2,265,339
Significance 6/10

CCO Moat Ross sells 87,269 shares ($2.3M) across 2 transactions; holds 9,415 shares post-sale (-90.3% reduction)

Moat Ross, Chief Commercial Officer, executed 2 separate sales totaling 87,269 shares for $2,265,339.03, reducing his holdings from 96,684 shares to 9,415 shares—a -90.3% net reduction. The blended average sale price of $25.96 sits below the current price of $27.74, yet his prior sales at KNSA (both on 2024-09-03) were well-timed: the 90-day post-sale returns were -16.3% and -19.4%, respectively, indicating a pattern of selling before subsequent declines. The company has demonstrated strong recent revenue growth of +56.6% annually and a positive latest-quarter net income of $8,539,000.00, though it remained unprofitable on a full-year basis. The near-complete liquidation of a long-held position by the Chief Commercial Officer warrants attention to whether this reflects a change in conviction or confidence in the company's near-term outlook.

September 2024
Sell
68,506 shares
$1,789,190
Significance 6/10

KNSA CCO Moat Ross sold 68,506 shares for $1.8M at $26.12 avg, cutting stake 75.9%; stock near 52-wk highs.

Moat Ross, Chief Commercial Officer, completed 2 separate sales totaling 68,506 shares for $1,789,189.80 at a blended average price of $26.12 on 2024-09-03, reducing his post-transaction holdings to 21.7K shares from 90.2K shares. The $26.12 transaction price sits near the 52-week high of $27.55, within 5.5% of the peak. The stock has appreciated 31.9% over the past 90 days and 6.8% over 30 days, suggesting this sale occurred during a period of sustained upward momentum. The company posts quarterly revenue of $108.6M with annual growth of 22.7%, but carries a net loss of $3.9M, and the P/E of 128.70 reflects elevated valuation expectations typical of unprofitable growth companies. No trading plan FLAG is specified in the FACTS provided.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access